Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Spyre Therapeutics, Inc.

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

SYRE

NASDAQ:SYRE

Spyre Group

Last Close

37.69

08/11 21:00

Market Cap

1.42B

Beta: 2.85

Volume Today

426.80K

Avg: 211.16K

PE Ratio

−1.71

PFCF: −13.46

People Not Available